Brightgene Bio-medical Technology Co (SHSE:688166) Short-Term Debt: ¥69 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688166 Brightgene Bio-medical Technology Co Ltd SHSE:688166
82 GF Score
Price ¥40.24
GF Value ¥38.68
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Brightgene Bio-medical Technology Co Short-Term Debt?

Brightgene Bio-medical Technology Co SHSE:688166 +7.56% 82 Short-Term Debt is ¥69 Mil as of Mar. 2026. GuruFocus rates SHSE:688166 with a GF Score™ of 82/100 and a GF Value™ of ¥38.68 (Fairly Valued). The stock has 7 warning signs investors should review.

Brightgene Bio-medical Technology Co's Short-Term Debt for the quarter that ended in Mar. 2026 was ¥69 Mil.

Brightgene Bio-medical Technology Co's quarterly Short-Term Debt declined from Sep. 2025 (¥149 Mil) to Dec. 2025 (¥110 Mil) and declined from Dec. 2025 (¥110 Mil) to Mar. 2026 (¥69 Mil).

Brightgene Bio-medical Technology Co's annual Short-Term Debt declined from Dec. 2023 (¥157 Mil) to Dec. 2024 (¥115 Mil) and declined from Dec. 2024 (¥115 Mil) to Dec. 2025 (¥110 Mil).

Brightgene Bio-medical Technology Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Brightgene Bio-medical Technology Co Short-Term Debt Related Terms

Brightgene Bio-medical Technology Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Brightgene Bio-medical Technology Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brightgene Bio-medical Technology Co Short-Term Debt Chart

Brightgene Bio-medical Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 257.06 124.38 156.87 115.26 110.11

Brightgene Bio-medical Technology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 131.42 168.73 149.27 110.11 68.93
SHSE:688166
82GF Score
Brightgene Bio-medical Technology Co Ltd SHSE:688166
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥69 Mil mean?
Brightgene Bio-medical Technology Co (SHSE:688166) has a Short-Term Debt of ¥69 Mil as of Mar. 2026.
Is Brightgene Bio-medical Technology Co's Short-Term Debt too high?
Brightgene Bio-medical Technology Co's current Short-Term Debt is ¥69 Mil. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's Short-Term Debt compare to VRTX and REGN?
Brightgene Bio-medical Technology Co's Short-Term Debt of ¥69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Brightgene Bio-medical Technology Co's current Short-Term Debt is ¥69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Fairly Valued. The stock's GF Value™ is ¥38.68, compared to a current price of ¥40.24 — trading 4% above its estimated fair value. The current Short-Term Debt is ¥69 Mil. Brightgene Bio-medical Technology Co's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current Short-Term Debt is ¥69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?

Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be overvalued. The current stock price of ¥40.24 is trading 4% above its estimated GF Value™ of ¥38.68. GuruFocus considers Brightgene Bio-medical Technology Co to be Fairly Valued.

Key valuation signals for SHSE:688166:

  • Short-Term Debt: ¥69 Mil
  • GF Value™: ¥38.68 vs. price of ¥40.24 (4% above fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Brightgene Bio-medical Technology Co Business Description

Address No. 218 Xinghu Street, Buildings C25-C28, Nanotechnology Park, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
82GF Score

Get the complete analysis for SHSE:688166

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥40.24
Price
¥38.68
GF Value